RxDoctor Payments Data

Mark Shermer, MD

Nephrology · Memphis, TNNPI 1144306366

Payments from drug & device makers

$1,253in general payments, 2019–2025

Across 47 payments — averaging $26.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Fresenius USA Marketing, Inc.$296
  • AstraZeneca$242
  • Mallinckrodt Enterprises LLC$165
  • Johnson & Johnson$119
  • Otsuka America Pharmaceutical, Inc.$114
  • Medtronic$64
  • plus $253 from 8 others

What the payments were for

  • Food & beverage$1,08587%
  • Education$16713%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,253 in reported general payments places this provider in the 45th percentile of 229 nephrology providers in Tennessee.

See all nephrology providers in Tennessee

Medicare billing

Part B allowed, 2024
$242,539
Medicare patients
449
Services billed
2,208

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JynarqueTolvaptan13$256,768
VelphoroSucroferric Oxyhydroxide120$240,822
AuryxiaFerric Citrate25$45,398
FarxigaDapagliflozin Propanediol38$36,709
Sevelamer Carbonate155$14,532
LokelmaSodium Zirconium Cyclosilicate13$9,603
Calcitriol179$4,027
Hydralazine Hcl79$1,292
Cinacalcet Hcl17$1,279
Midodrine Hcl16$1,093
Labetalol Hcl16$1,051
Ondansetron OdtOndansetron20$728
Allopurinol64$584
Losartan Potassium49$403
Clonidine Hcl31$366

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Jynarque$114$256,76813 claims
Fresenius USA Marketing, Inc.Velphoro$296$240,822120 claims
AstraZenecaFarxiga, Lokelma$242$46,31251 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 229 nephrology providers in Tennessee.

Other nephrology in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →